Get the Daily Brief
Latest Biotech News
Sanofi snaps up Dynavax for $2.2B — MS drug hits CRL
Sanofi agreed to acquire Dynavax Technologies for $2.2 billion in cash, buying a commercial hepatitis B vaccine (Heplisav‑B) and a phase I/II shingles candidate, according to company announcements...
Medicare to test GLP‑1 coverage — obesity access threshold crossed
CMS announced a voluntary model to enable Medicare Part D plans and state Medicaid programs to cover GLP‑1 drugs for weight management, marking a threshold event in U.S. obesity care policy. The...
FDA greenlights first TA‑TMA drug: Omeros’ Yartemlea cleared
The U.S. Food and Drug Administration approved Yartemlea (narsoplimab) from Omeros as the first treatment for hematopoietic stem cell transplant‑associated thrombotic microangiopathy (TA‑TMA), the...
Court voids FDA LDT rule — regulatory landscape upended
A federal court struck down the FDA’s final rule to regulate lab‑developed tests (LDTs), marking a major legal reversal for the agency and reshaping diagnostics oversight in 2025. The decision...
Engineered vesicles revive oral antibiotics — gut spared
Researchers published in Nature Communications that engineered vesicles can increase oral antibiotic absorption while protecting the gut microbiome, reporting both improved drug bioavailability...
Intraperitoneal mRNA programs CAR macrophages — new in‑body cell therapy
Researchers demonstrated intraperitoneal delivery of mRNA lipid nanoparticles that program CAR macrophages in situ, enhancing antitumor activity within the peritoneal cavity. The study showed that...
Vyriad closes $25M tranche — in vivo CAR‑T candidate moves to humans
Vyriad closed a $25 million final tranche to its Series B, bringing the round to $85 million, to support first‑in‑human testing of VV‑169, an in vivo CAR‑T candidate for relapsed or refractory...
Enveda starts Phase I of ENV‑6946 — first‑in‑class oral IBD candidate
Enveda Therapeutics received FDA IND clearance and initiated a Phase I trial of ENV‑6946, a first‑in‑class oral small molecule for inflammatory bowel disease, including ulcerative colitis and...
ADC targets mapped across breast cancer metastases — Nature study
A Nature Communications study by Borremans, Pabba, Zels and colleagues profiled expression of antibody‑drug conjugate (ADC) targets across breast cancer metastases and matched normal tissues,...
FDA clears Crescom’s AI bone‑age tool — pediatric device OK'd
Crescom Co. Ltd. received U.S. FDA 510(k) clearance for MediAI‑BA, an AI‑powered pediatric and adolescent bone age analysis software. The device, classified as class II, estimates bone age and...
Sanofi pays $2.2B for Dynavax: HepB vaccine added to lineup
Sanofi agreed to acquire Dynavax Technologies for about $2.2 billion in cash, buying a commercial hepatitis B vaccine and a clinical‑stage shingles candidate. The firms announced the deal as...
Medicare to test GLP‑1 coverage: obesity‑drug access threshold crossed
CMS announced a voluntary model test that would enable Medicare Part D plans and state Medicaid programs to cover GLP‑1 drugs for weight management, marking a threshold shift in public‑payer...
FDA approves Omeros’ Yartemlea: first TA‑TMA therapy
The U.S. Food and Drug Administration approved Omeros Corporation’s Yartemlea (narsoplimab) as the first indicated therapy for hematopoietic stem cell transplant‑associated thrombotic...
Court strikes down FDA’s LDT rule — regulatory year‑end shock
A federal court ruled against the FDA’s final rule to regulate laboratory‑developed tests (LDTs), overturning an agency effort to bring many LDTs under stricter federal oversight. Legal challenges...
HHS proposes rollback: cuts health‑tech certification and AI transparency
HHS published a proposed rule that would roll back multiple Biden‑era policies, pare back health‑tech certification criteria and remove planned transparency requirements for healthcare AI tools....
Crescom wins FDA clearance for MediAI‑BA: pediatric bone‑age AI cleared
Crescom Co. Ltd. received FDA 510(k) clearance for MediAI‑BA, its AI‑powered software that evaluates pediatric and adolescent bone age and predicts adult height from hand and wrist X‑rays. The...
Vyriad closes $25M tranche — $85M series B backs VV‑169 trial
Vyriad Inc. closed a final $25 million tranche of its series B, bringing total series B financing to $85 million to support first‑in‑human testing of VV‑169, an in vivo CAR T candidate targeting...
Engineered vesicles boost oral antibiotics: improve absorption, spare gut flora
Researchers published in Nature Communications an engineered vesicle approach that enhances oral antibiotic absorption while reducing gut dysbiosis. The study demonstrated that tailored vesicles...
Intraperitoneal mRNA CAR macrophages — in‑body programming enhances tumor killing
Researchers reported an intraperitoneal delivery method using mRNA lipid nanoparticles to program CAR macrophages in situ, boosting antitumor activity in peritoneal cancer models. The approach...
Enveda gets IND for ENV‑6946: first‑in‑human IBD trial starts
Enveda Biosciences secured FDA IND clearance and initiated a phase I trial of ENV‑6946, a first‑in‑class oral small molecule candidate for inflammatory bowel disease, including ulcerative colitis...